Rapamycin for Dogs in 2026: What Every Senior Dog Owner Should Know

Rapamycin (also called sirolimus) is an FDA-approved drug in humans, originally used as an immunosuppressant after organ transplants. In lower doses, it's being studied for its potential to extend healthspan and lifespan by targeting a cellular pathway called mTOR (mechanistic target of rapamycin).

mTOR inhibition: The mTOR pathway regulates cell growth, metabolism, and aging. When overactive, it's linked to accelerated aging, inflammation, and age-related diseases. Rapamycin "dials down" mTOR activity, mimicking some benefits of caloric restriction without requiring your dog to eat less.

Immune modulation: At the doses being studied for longevity (much lower than transplant doses), rapamycin may improve immune function in aging dogs rather than suppress it. Early research suggests it can help "reset" the aging immune system.

In lab studies, rapamycin extended lifespan in mice by 9-14%. The question for dog owners: does it translate to companion animals?

The largest rapamycin study in dogs is the TRIAD (Test of Rapamycin in Aging Dogs) trial, run by the University of Washington's Dog Aging Project. It's funded by a $7 million NIH grant and aims to enroll 580 dogs aged 7+ years, weighing 44+ pounds.

Current status (Feb 2026): Over 180 dogs enrolled so far. The trial is ongoing, with results expected by 2029.

What they're measuring: The trial tracks cardiac function, cognitive performance, immune markers, and overall healthspan. Unlike pharmaceutical trials, TRIAD is a research study — not an FDA approval pathway.

Prior research: A 2016 pilot study at Texas A&M showed that 10 weeks of rapamycin improved heart function in middle-aged dogs. A 2017 follow-up found no significant side effects in dogs given low-dose rapamycin for 10 weeks.

The Dog Aging Project also runs an open observational study where owners can report their dogs' experience with rapamycin prescribed by their own vet. This data feeds into the broader research effort.

Here's what many senior dog owners don't realize: rapamycin is already available. It's an FDA-approved drug for humans, which means veterinarians can legally prescribe it "off-label" for dogs.

Off-label use means using an approved drug for a purpose not listed on the official label. It's common in veterinary medicine — many drugs used daily in vet clinics are human medications prescribed off-label.

Some progressive veterinarians are already prescribing rapamycin for healthy aging in senior dogs, typically starting around age 7-10. Others are waiting for more data before recommending it outside of clinical trials.

The catch: Because it's not officially approved for longevity in dogs, insurance won't cover it, and dosing protocols vary between vets. You're relying on your vet's judgment and emerging research, not standardized guidelines.

If you're interested, the conversation typically starts with: "I've been reading about the Dog Aging Project's rapamycin research. Is this something you'd consider for [dog name] given their age and health status?"

Typical dosing (based on TRIAD and off-label use):

• Weekly dosing: Most protocols use once-weekly dosing rather than daily. Common range: 0.05-0.15 mg/kg body weight per week.
• Example: A 50-pound (22.7 kg) dog might receive 1-3 mg of rapamycin once per week.
• Adjustment period: Vets often start at the lower end and adjust based on bloodwork and response.

Cost:

• Generic rapamycin (sirolimus): approximately $30-80/month for a 50-pound dog, depending on dose and pharmacy.
• Add vet visit costs for initial consultation, baseline bloodwork, and periodic monitoring (typically every 3-6 months).
• Total first-year cost estimate: $800-1,500 including monitoring.

Reported side effects (from TRIAD and observational data):

• Diarrhea: The most common side effect, typically mild and temporary. Usually resolves within the first few weeks or with dose adjustment.
• Decreased appetite: Some dogs eat less initially. Monitoring weight is important.
• Elevated cholesterol/triglycerides: Can occur but is usually manageable. Bloodwork monitoring catches this early.
• Rare: delayed wound healing or increased infection risk (more common at immunosuppressive doses, less common at longevity doses).

Most dogs tolerate low-dose rapamycin well. The Dog Aging Project's pilot studies reported a low discontinuation rate due to side effects.

LOY-002 and rapamycin are often mentioned together, but they're fundamentally different approaches to dog longevity. Here's how they compare:

The balanced take: Rapamycin shows genuine promise, but we're still in the "promising but early" phase for dogs.

Consider asking your vet if:

• Your dog is 7+ years old and in generally good health
• You're willing to commit to regular bloodwork monitoring
• Your vet is familiar with the Dog Aging Project research and comfortable with off-label prescribing
• You understand this is not a "proven" longevity drug yet — it's an informed bet based on early evidence
• You can afford $800-1,500/year including monitoring costs

Wait for more data if:

• Your dog has pre-existing immune issues, wound healing problems, or chronic infections
• You prefer standardized, FDA-approved protocols (LOY-002 may arrive within 1-2 years)
• Your vet isn't comfortable prescribing it off-label yet
• You want to see the full TRIAD trial results before committing

There's no "wrong" choice here. Some owners are comfortable being early adopters based on existing evidence. Others prefer to wait for definitive results. Both are rational positions.

What you can do now: Track your dog's baseline health data (weight, energy, symptoms) so you have a clear picture if and when you start any longevity intervention. Whether it's rapamycin, LOY-002, or something else, having before/after data makes the difference between guessing and knowing.

If you do start rapamycin (or any longevity drug), tracking interactions with other medications and supplements becomes critical. Rapamycin can interact with certain drugs, including some antibiotics, antifungals, and supplements like St. John's Wort.

FursBliss includes an interaction checker for logged medications and supplements. You can:

• Log all medications and supplements your dog takes
• Get flagged warnings for known interactions
• Share a clean medication list with your vet before appointments
• Track which combination works (or doesn't work) over time

Our interaction checker cross-references the veterinary drug database and flags combinations that require vet review. It's not a replacement for veterinary judgment — it's a safety net to ensure nothing gets missed.

Try the interaction checker or see breed-specific health tracking for Golden Retrievers, Labrador Retrievers, German Shepherds, and 100+ other breeds.

Rapamycin is the most accessible dog longevity option available today. It has decades of human safety data, promising early results in dogs, and a major NIH-funded trial underway.

It's also still experimental for longevity purposes. The TRIAD trial won't conclude until 2029. Off-label use means you're making a decision with incomplete data — but with more evidence than we've ever had before.

If your dog is entering their senior years, the smartest first step isn't choosing a drug. It's establishing baseline health data. Track their weight, energy, symptoms, and vet visits now so you have a clear "before" picture for any intervention you consider later.

The goal isn't just more years. It's more good years.